Nice short squeeze candidate, it may have even begun!Nice short squeeze candidate, it may have even begun! I know nothing about this company, hell I don't need too I just chart and use finintel and keep it simple stupid (KISS) and keep it moving in and out like a ninja! GLTALongby candlestickninja0
A Technical Dissection of ABIO's RallyARCA biopharma, Inc. (NASDAQ: ABIO) exhibited a parabolic ascent on the trading session following the announcement of an all-stock merger with Oruka Therapeutics, a transaction poised to diversify the company's dermatological biologics portfolio. The equity's volume thrust was monumental, significantly eclipsing its 50-day average, indicating an accumulation of shares amidst heightened investor interest. Technically, the security's Relative Strength Index (RSI) flirts with the upper echelons of the overbought territory, suggesting a near-term consolidation could ensue as the stock digests its recent gains. It is pivotal for investors to monitor any potential RSI divergence that could preclude a momentum reversal. The Moving Average Convergence Divergence (MACD) oscillator corroborated the bullish fervor with a pronounced divergence from its signal line, a harbinger of sustained upward price momentum, albeit within the context of an imminent volatility expansion given the enormity of the price gap introduced in the session. A Fibonacci retracement, applied to the stock's trajectory from its nadir to zenith, may elucidate potential support and resistance fulcrums that could dictate price action in forthcoming sessions. Given the extent of the gap, a retracement to the 38.2% level could be construed as a healthy retrace offering a secondary entry point for momentum traders. The salient price gap serves as a testament to the market's recalibration of the firm's intrinsic valuation post-merger announcement, an ineffaceable beacon that could either cement itself as a new support bastion or an overhang of resistance in the event of a pullback. Investors should remain vigilant for the establishment of a support base post-gap, which would serve as a bellwether for the stock's ability to retain its accrued value from the catalytic merger event. The confluence of technical indicators and underlying volume suggests a bullish impetus in the interim, contingent upon forthcoming quarterly financial disclosures and market assimilation of the merger's strategic implications.by AxiomEx2
ARCA biopharma Buy TF D1 TP = 2.81On the daily chart the trend started on January 27 (linear regression channel). And it is still not closed according to my calculations. There is a high probability of profit taking. Possible take profit level is 2.81 But we should not forget about SL = 1.84 Using a trailing stop is also a good idea! Please leave your feedback, your opinion. I am very interested in it. Thank you! Good luck! Regards, WeBelieveInTradingLongby WeBelieveInTrading0
ABIO NOV 28 2021I think we have a good setup here for a long position. Stop loss under last candle.Longby HeyHoTrader0
ARCAAnother extreme oversold small bio cap. Arca Biopharma Inc (NASDAQ:ABIO) touched a new 52 week low last week and closed at $2.36 a share on Friday. I think now is the time to start trying to catch this knife. Alone this company has more cash ($4 per share) than current market capitalization. Cash and cash equivalents were $58.3 million as of September 30, 2021, and they believe that its current cash and cash equivalents will be sufficient to fund its operations through 2022. Furthermore, the stock could get a boost from the current increase of the COVID cases worldwide, especially in Europe. According to CEO Dr. Michael Bristow, with rNAPc2’s combination of anticoagulant, anti-inflammatory and potential antiviral properties, he believes it has the potential to be effective in addressing COVID-19 impacts in hospitalized patients. The international Phase 2b clinical trial is nearing completion and they look forward to sharing its results in the first quarter. I have been accumulating shares again.Longby SmoothJB1
ABIO Caught Between Two FibsOn this episode of "Between Two Fibs" ABIO once again tested the 618 line plotted after using the recent low as the anchor. This has been a failure point 2 other times in the last few weeks but with a little more afternoon momentum, it will be interesting to see if it can break and hold above it. Other than that, the 786 fib appeared to have acted as lower support a few times prior to gapping down recently. With today's big swing, that could be another key level for ABIO to hold at or above. See More: 3 Biotech Penny Stocks To Watch On Robinhood IPO Day by PennyStocks1011
ABIO - Pump & Dump - BUY +500%VERY RISKY, VERY LONG TERM INVESTMENT in Penny Stocks!!! Not a financial advice! Buy - 3.50 TP - Sell limit at 21$ (2/3 of shares purchased) 1/3 - if go more up. Good Luck!Longby GlebInvestor0
ABIO a great long opportunity!ARCA biopharma Inc is a biopharmaceutical company. It applies precision medicine approach to develop genetically targeted therapies for cardiovascular diseases. The firm's lead product candidate is Gencaro. The company adopts genotype-directed comparative effectiveness trial of Bucindolol and Toprol-XL for prevention of symptomatic atrial fibrillation in patients with heart failure. It establishes long-term relationships with partners such as Medtronic, Laboratory Corporation of America and the University of Colorado. If you understand the idea,🎯 press a thumb up! 👍👍👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!Longby TRADING_as_a_BUSINESS5
ARCA biopharma, Inc Alert above $6.20ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.Longby DEXWireNews111
TIME AND SPACE: Goodies under 6 for clear TPs @ $12 and $24Abio whilst currently tumbling down pyramid slope has no dilution risk with sufficient cash on hand to last a while based on current cash burn and has plenty catalysts. Geometric structure is very supportive of a move to $12 at minimum and more likely $24Longby joka21890
ABIO And Complete Recap Of My Stocks ExperienceI'm really into crypto and I've seen so many things not only from a trading perspective but also mining individual Scrypt + SHA-256 coins...Fidelity is just an island or oasis with the peace of mind when I execute a trade it goes through. I don't have lag, loss of connection, obfuscation or loss of funds from theft on exchanges part. I can put $500 or 2 million and I know that I'm going to be able to rest on weekends and past 6pm each day. With 2 children I have been happier with that schedule working on charts when I can get a minute... To recap to my followers who may have wondered what happened to me after I posted a BTC chart that went the opposite direction I took my funds out at $6.6k and entered them back at $9100. In the interm I was involved with a brand new experience with stocks which has been more lucrative with my time than trying to play the altmarket or even leveraging funds with crypto. I'll link some of the charts which may be active or completed to update my brand new experience. Thanks and take care!Longby TheCryptoChartWhispererUpdated 2
Massive squeeze potential in this biotech stockThe company is a very small market cap so it's considerably higher risk than most stocks. Stocks like these require very small positions.Longby LanmarUpdated 4
ABIO: Currently looking for a Long EntryFirst off, please don't take anything I say as financial advice and as always everything is on an opinion based basis. Pursue your own due diligence. That being said, ABIO seems to have a decent setup for potentially another bull run quite soon. The resistance curve is about to pop and it looks like this is a close watch as with other stocks I been watching. In my opinion the risk isn't too high given the mostly neutral pattern after the bearish action that happened kicking off June. At that point, the risk got mostly reduced and this price for an entry isn't too bad. It still though is risky.Longby gamer4561484
ARCA BIOPHARMA INCNASDAQ:ABIO Another possible short for today. After a sharp rise on May 28, the paper could not grow any further. All the growth has already been sold. At 6.81 instrument faced a strong support level. Within 3 days there were a level tests. On June 22, the big long player managed to raise the price slightly from 6.89 to 7.52. However, in the last trading session the short player pushed the price down again. We can see the struggle of two strong players for the price. It is quite possible that today the support level will be broken through in the close retest. The safest scenario is to enter the short only after the break-down and fixing the price under the level. If the price can't get fixed, it is not recommended to enter the short because there are obviously two strong opposite players, further struggle is possible. Shortby AllexMl5